DarioHealth Corp., a pathfinder in the global digital therapeutics market, announced the launch of a new virtual care initiative with MediOrbis- a telehealth provider specializing in chronic conditions. DarioHealth will provide Remote Patient Monitoring Services to MediOrbis for New Offering to Medicare Patients with Diabetes.
- The virtual care program will be made available to Dario’s approximately 75,000 members with diabetes, of which 30% are over 65. Eligible Medicare members, who have diabetes, can receive suitable virtual care, including telehealth delivered by MediOrbis and remote patient monitoring through DarioHealth’s AI-powered digital chronic care platform under their existing Medicare benefit.
- This will allow current Dario members to obtain high-quality, convenient care at a conceivably lower out-of-pocket cost. Also, the virtual care program will be exchanged with qualified Medicare members, who aren’t currently using Dario’s offering. This factors a significant expansion possibility for Dario’s remote patient monitoring business.
- The virtual services now on a grant through the app include primary and acute care; chronic disease management for conditions such as diabetes, hypertension, and COPD; and specialty consultations or second opinions for more complicated medical concerns. These telehealth features come alongside DarioHealth’s core system: a disease-tracking and management app, as well as a connected phone attachment housing a lancing device, glucose meter and a testing-strip holder.
- Rick Anderson, President, and General Manager North America said,” “We are thrilled to partner with MediOrbis to launch this virtual care service for qualified Medicare beneficiaries. Offering our existing users this program, provides users with enhanced services and support at a lower cost increasing our offerings to existing customers across all of our market segments is part of our strategy to improve value to our users while increasing revenue per member and lowering our average member acquisition cost”.